Definium Therapeutics Inc.

DFTX | NASDAQ

Price Alert Chart Builder DCF Calculator

$36.33

-$1.63 (-4.29%)

At close: Oct 30, 2026, 4:00 PM ET

$36.37

+$0.04 (+0.11%)

Pre-market: Nov 2, 2026, 9:27 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $4.88B

Enterprise Value $3.83B

Beta 2.19

Average Volume 2.34M

Shares Outstanding (Diluted) 110.68M

Shares Change YoY 29.69%

Institutional Ownership N/A

Exchange NASDAQ

ISIN CA24477V1058

Price Performance

Price Change 1M -4.5%

Price Change 3M -16.5%

Price Change 6M 67.4%

Price Change YTD 171.3%

Price Change 1Y 155.8%

Price Change 3Y 1319.1%

Price Change 5Y -3.9%

1M CAGR (ann.) -6.4%

1Y CAGR (ann.) 181.4%

5Y CAGR (ann.) -0.1%

All-Time CAGR 26.9%

Valuation

PE Ratio -10.59

Forward PE N/A

PEG Ratio 0.14

Forward PEG -0.18

PS Ratio N/A

Forward PS 166.30

PB Ratio 5.31

P/FCF Ratio -29.25

P/Adj. FCF Ratio -24.30

P/OCF Ratio -24.06

EV/Sales N/A

EV/EBIT -11.27

EV/EBITDA -11.29

EV/FCF -22.98

Earnings Yield -9.4%

FCF Yield -3.4%

Adj. FCF Yield -4.1%

Financial Health

Net Cash $1.05B

Total Debt $36.47M

Cash & Short-Term Investments $1.08B

Total Assets $1.11B

Current Ratio 6.95

Quick Ratio 6.95

Debt / Equity Ratio 0.04

Debt / EBITDA -0.11

Debt / FCF -0.22

OCF / Debt -4.58

Interest Coverage -16.92

Altman Z-Score 14.05

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -20.4%

Returns

Return on Assets -31.8%

Return on Equity -85.2%

Return on Invested Capital -23.8%

Return on Capital Employed -23.8%

Return on Tangible Assets -32.4%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -24.6%

EPS CAGR 5Y 15.8%

EPS CAGR 10Y 9.7%

FCF CAGR 3Y -40.8%

FCF CAGR 5Y -29.9%

FCF CAGR 10Y -33.4%

Analyst Forecasts

Analyst Rating Buy

Analyst Count 12

EPS Growth Next 3Y 44.0%

Revenue Growth Next 3Y N/A

Earnings Date Nov 9, 2026

EPS Estimate (next Q) -$0.56

EPS Growth Est (next Q) -27.8%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $67.45

Price Target Upside 85.7%

Cash Flow

Operating Cash Flow $-166.87M

Free Cash Flow $-166.87M

Adj. Free Cash Flow $-200.87M

FCF Per Share -$1.51

OCF Per Share -$1.51

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $0

Operating Income $-227.54M

EBITDA $-339.7M

Net Income $-353.79M

EPS (Diluted) -$3.43

Revenue / Employee N/A

Profit / Employee $-3.34M

Employees 106